• Postoperative endophthalmitis caused by cutibacterium (formerly Propionibacterium) Acnes: case series and review
• Pneumatic release of focal vitreomacular traction
• Ocular findings in infants with microcephaly associated with presumed Zika virus congenital infection in Salvador, Brazil
• Vitrectomy for primary symptomatic vitreous opacities: an evidence-based review
• Intraoperative optical coherence tomography: past, present, and future
• Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes?Protocol 3 with high dose)
• The next generation of artificial vision
• Telescopic lens helps patients with dry AMD
• Epigenetic modifications and potential new treatment targets in diabetic retinopathy
• Surgical management of suprachoroidal hemorrhage

Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes?Protocol 3 with high dose)
D V Do. Eye (2015) 29, 1538-1544

Se presentan los resultados de un corte parcial del ensayo clínico aleatorizado, controlado, multicéntrico: Ranibizumab para el edema de la mácula en la diabetes- Protocolo 3 (READ-3). Se analizó el cambio en la agudeza visual mejor corregida a los 6 meses, así como la variación del grosor foveal central y las reacciones locales y sistémicas por la aplicación del tratamiento con ranibizumab en una dosis alta (2 mg).